Comparative pharmacokinetics of two formulations of 2.5-mg rivaroxaban in healthy Korean subjects.

The pharmacokinetic parameters of rivaroxaban were compared between the test and reference drug, and both formulations were bioequivalent. The newly developed rivaroxaban tablet is safe and well tolerated as the reference drug (ClinicalTrials.gov identifiers: NCT05418803).